You just read:

New analysis showed dose adjustment of Gilotrif® (afatinib) improved tolerability without an apparent impact on efficacy in patients with EGFR mutation-positive non-small cell lung cancer

News provided by

Boehringer Ingelheim Pharmaceuticals

Sep 08, 2016, 08:00 ET